Judges Deny Challenge to Psilocybin Patent
The Patent Trial and Appeal Board decided that petitions against Compass Pathways' psilocybin patents would not move forward to trial.
Can the Clever Use of Old Legal Strategies Thwart Psychedelic Monopolies?
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
The Battle Over Psychedelic Therapy's Future
In a new documentary, VICE News explores what legal psychedelic therapy and access will be like in the US, and if it will be accessible.
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It
For-profit companies want psychedelics to be treated as medicine; others want them to just be legal. They'll have to learn to get along.
Psychedelics Patent Claim Raises Questions From Researchers Who Say They Did It First
A recent application from CB Therapeutics on biosynthetic psilocybin is emblematic of the IP concerns around novelty and obviousness the psychedelic field will face.
Is it Possible to Create an Ethical Psychedelics Company?
The debate around psychedelic patents reflects a deeper question about how to create a business model that puts values before profits.
Investors Are Debating Who Should Own the Future of Psychedelics
In a series of open letters and statements, investors have been debating how patents will shape the future—who will get to use psychedelics, and who will profit.
Can a Company Patent the Basic Components of Psychedelic Therapy?
Compass Pathways, a Peter Thiel-backed psychedelic mental health company, has made patent application claims on aspects of psilocybin-assisted therapy as basic as using soft furniture and holding hands.
The FDA Just Fast-Tracked Another Psychedelic Medicine Trial
Don’t expect to pick up prescription shrooms at CVS, though.